SLC5A2 and Renal insufficiency: For example, the 24 h UGE with treatment of dapagliflozin was decreased by 42%, 83%, and 84% in patients with mild, moderate, and severe renal insufficiency, respectively (Kasichayanula et al., 2013), further supporting the notion that reduced efficacy of SGLT2 inhibitors in patients with renal insufficiency correlates with impaired SGLT2 transporter function.